Quanterix and Banyan Biomarkers Join Together to Address Traumatic Brain Injury Head On

August 1, 2016

Lexington, Mass. – August 1, 2016  — Quanterix Corporation, a leader in the transformation of healthcare through its ultrasensitive single molecule testing capabilities, today announced a license agreement for research use with Banyan Biomarkers, a pioneering company in the development of biomarkers for traumatic brain injury (TBI). Quanterix’ Simoa platform will incorporate the Banyan UCH-L1™ and Banyan GFAP™ assays to help further neurological research for improved TBI diagnosis and treatment.  

“We look forward to collaborating with Quanterix to bring this important test to the labs of researchers studying brain injury. The ability to utilize an ultra-sensitive platform in combination with our proprietary biomarkers opens the possibilities for neurological discoveries that have the potential to improve the lives of millions of patients,” stated Hank Nordhoff, Chairman and CEO of Banyan Biomarkers.

According to the CDC, there are over 2.5 million emergency department visits, hospitalizations, or deaths related to TBI, either alone or in combination with other injuries, each year. This results in costs exceeding $82 billion annually, which is a significant burden to the US healthcare system.” 

“With the growing awareness of the short-term and long-term consequences of concussions and repetitive mild TBI, including neurodegenerative diseases such as Chronic Traumatic Encephalopathy (CTE), we’re in desperate need of new objective methods to quickly and accurately diagnose patients for improved treatment and prognoses,” said Robert Stern, PhD, Professor of Neurology and Director of Clinical Research at the Alzheimer’s Disease and Chronic Traumatic Encephalopathy Center, Boston University. “Quanterix is working with select partners to do just that. It’s exciting to see the significant strides the company is making in the neurology space, and I look forward to seeing the impact that Simoa will have on the future of brain health.”

 

Quanterix is working with companies, like Banyan, to provide the tools necessary for researchers to better understand neurological disorders and how to best treat them. The company’s ultrasensitive Simoa technology can detect biomarkers associated with brain injury and disease at much earlier stages to understand the long-term effects and disease pathology. Simoa has already been used in several neurology-focused research programs across a wide range of variables and demographics, including professional hockey players, Olympic boxers, military personnel, as well as professional football players.

“This exciting partnership with Banyan is further evidence of our commitment to driving meaningful advancement in the neurology space,” said Kevin Hrusovsky, CEO and Executive Chairman, Quanterix. “We made significant strides with our recent focus on TBI, and look forward to continuing to expand our efforts in all areas of neurology to improve research, drug development and, ultimately, diagnostics. As we continue to develop informative biomarkers that report on neural and inflammation-related biology – and put these together in multiplex formats – we will be best positioned to develop the most accurate and predictive tests for concussions, CTE, TBI and other neurological disorders.”

Quanterix is focused on aggressively expanding its biomarker menu for all therapeutic areas, with a continued emphasis on neurology. This partnership is supporting the company’s goal of growing their assay menu from 40 to 80 assays by the end of 2016, with the addition of Banyan’s GFAP™ and UCH-L1™ biomarkers. These biomarkers will expand Simoa’s applications to include a broader range and more informative view of biological health status post-head trauma and will be valuable for the assessment of disease-induced neural damage. Quanterix will also be including these markers in a set of neuro-multiplex assays, which as a panel, will be highly informative to research in this therapeutic area.

Quanterix will be exhibiting at the 68th AACC Annual Scientific Meeting & Clinical Lab Expo this week in Philadelphia, PA and can be found at booth #4273.

To learn more about Simoa, please visit: http://www.quanterix.com/products/simoa-hd-1-analyzer.

About Banyan Biomakers:

Banyan Biomarkers, Inc. is focused on developing a blood test that could be used by physicians and healthcare providers to rapidly and objectively detect the presence of mild and moderate TBI and improve the medical management of head injured patients. The Company’s test uses two brain specific protein biomarkers (Banyan UCH-L1™ and Banyan GFAP™) that rapidly appear in the blood after a brain injury. The development of this blood based TBI test is being supported by significant funding from the United States Department of Defense. To learn more about Banyan Biomarkers, visit www.banyanbio.com.

 

About Quanterix

Quanterix is a developer of groundbreaking tools in high definition diagnostics. Its Simoa platform uses single molecule measurements to access previously undetectable proteins. With this unprecedented sensitivity and full automation, Simoa offers significant benefits to both research and clinical testing applications. Quanterix was established in 2007 and is located in Lexington, Massachusetts.  To learn more about Quanterix and Simoa, please visit:www.quanterix.com. Investors can access a webcast of Kevin Hrusovsky’s recent JPMorgan presentation at:http://info.quanterix.com/watch-quanterix-jp-morgan-healthcare-presentation.

 

Caitlyn Keating
PAN Communications
617-502-4300
quanterix@pancomm.com

 

Tony Grover
Banyan Biomarkers, Inc.
Vice President of Business Development
617-502-4300
tgrover@banyanbio.com